Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Stage of Development | 8 | 1 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Therapy Area | 9 | 1 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Indication | 10 | 1 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Companies | 13 | 2 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Products under Development by Universities/Institutes | 15 | 2 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Therapeutics Assessment | 17 | 7 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 2 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Companies Involved in Therapeutics Development | 24 | 6 |
| Alkermes Plc | 24 | 1 |
| Biomar Microbial Technologies | 25 | 1 |
| Cyxone AB | 26 | 1 |
| OncBioMune Pharmaceuticals Inc. | 27 | 1 |
| Transgene SA | 28 | 1 |
| ZIOPHARM Oncology, Inc. | 29 | 1 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Drug Profiles | 30 | 12 |
| ALKS-4230 Drug Profile | 30 | 1 |
| Biologic to Activate IL-2 for Graft Versus Host Disease Drug Profile | 31 | 1 |
| BNZ-1321 Drug Profile | 32 | 1 |
| IB-08C175 Drug Profile | 33 | 1 |
| Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology, Central Nervous System and Gastrointestinal Disorders Drug Profile | 34 | 1 |
| Prostatac Drug Profile | 35 | 2 |
| T-20K Drug Profile | 37 | 1 |
| TG-4010 Drug Profile | 38 | 4 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Dormant Projects | 42 | 3 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Discontinued Products | 45 | 1 |
| Interleukin 2 (T Cell Growth Factor or Aldesleukin or IL2) Featured News &Press Releases | 46 | 11 |
| May 25, 2016: Alkermes Announces Initiation of Phase 1 Clinical Study of Immuno-Oncology Drug Candidate ALKS 4230 | 46 | 1 |
| May 18, 2016: Doctors Voice Optimism About Phase 2 Trial of ProscaVax in Mexico for Prostate Cancer | 46 | 1 |
| May 11, 2016: OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer | 47 | 1 |
| May 04, 2016: OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer | 48 | 1 |
| Apr 28, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China | 49 | 1 |
| Apr 12, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Hong Kong | 49 | 1 |
| Mar 29, 2016: Multiple sclerosis: plant peptide could prevent onset of the disease | 50 | 1 |
| Mar 16, 2016: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in Europe | 51 | 1 |
| Feb 23, 2016: OncBioMune Continuing Phase 1 Trial, While Initiating Phase 2 Trial of ProscaVax for Prostate Cancer | 52 | 1 |
| Feb 10, 2016: Christian Gruber is "Inventor of the Year 2015" of MedUni Wien | 53 | 1 |
| Dec 23, 2015: Transgene Announces Publication in The Lancet Oncology of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer | 54 | 1 |
| Nov 10, 2015: OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax in China and Ukraine | 54 | 1 |
| Sep 08, 2015: Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer | 55 | 1 |
| Aug 19, 2015: Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer | 55 | 1 |
| Jun 01, 2015: Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer | 56 | 1 |
| Appendix | 57 | 2 |
| Methodology | 57 | 1 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 57 | 1 |
| Expert Panel Validation | 57 | 1 |
| Contact Us | 57 | 1 |
| Disclaimer | 58 | 1 |